AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 17, 2018 meeting

IV. Secretary’s report

V. New Business
   A. Proposed protocol for dupilumab (Dupixent®)
   B. Proposed Protocol for cannabidiol (Epidiolex®)
   C. Proposed protocol for pregabalin (Lyrica®)

VI. Informational Highlight/Report
   A. Opioid utilization review (October 2015 – September 2018)
   B. Informational Highlights/Reports
      2. Summary of DURB Action Items
      3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
         (b) Physician-administered/Antiviral drugs by amount paid
      4. Medication information:
         (a) FDA considers requiring co-prescribing overdose antidote to go along with opioids
         (b) Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment
         (c) Prescriptions – and overdoses – are skyrocketing for anti-anxiety drugs that make opioids even more lethal
         (d) FDA provides update on angiotensin II receptor blocker (ARB)) recalls including valsartan, losartan and irbesartan

VII. Referenced Material
   A. Proposed pancreatic enzymes protocol